CDK2 and breast cancer: CDK2 (Fig. 1b), like the targets of the recently approved breast cancer drug Ibrance, is a member of the cyclin-dependent kinase family of Ser/Thr protein kinases whose de-regulation occurs frequently in certain types of cancer [24].